Discoveries of several genetic mutations and deregulations common across multiple cancer types have allowed researchers to develop more targeted oncology therapies. These and other scientific breakthroughs have led the oncology market to focus primarily on targeted therapies. The excitement around targeted approaches to cancer treatment has even led to a new field of study—precision oncology. To execute precision medicine clinical trials, sponsors have adopted a range of new approaches, especially in early-stage studies.